JAZZ · Jazz Pharmaceuticals plc · Documents

May 7

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Revenue $897.84M ▼ 0.5% Net loss $92.54M Diluted EPS -$1.52

May 6

Earnings call

Q1 2025 earnings call

May 6

Current report 8-K

Financial results

Apr 25

Annual report 10-K/A Ended Dec 31

Annual report for the period ended Dec 31, 2024

Apr 21

Current report 8-K

Regulation FD disclosure, Other events

Apr 18

Tender offer SC TO-T/A

Tender offer

Apr 14

Tender offer SC TO-T/A

Tender offer

Apr 11

Tender offer SC TO-T/A

Tender offer

Apr 10

Tender offer SC TO-T/A

Tender offer

Apr 9

Tender offer SC TO-T/A

Tender offer

Apr 8

Current report 8-K Events of Apr 7

Entered into a material agreement

Apr 7

Tender offer SC TO-T/A

Tender offer

Apr 4

Tender offer SC TO-T/A

Tender offer

Apr 1

Tender offer SC TO-T/A

Tender offer

Mar 28

Tender offer SC TO-T/A

Tender offer

Mar 21

Tender offer SC TO-T

Tender offer

Mar 6

Tender offer SC TO-C

Tender offer

Mar 5

Current report 8-K/A Events of Mar 4

Entered into a material agreement, Regulation FD disclosure

Mar 5

Current report 8-K Events of Mar 4

Entered into a material agreement, Regulation FD disclosure

Mar 5

Tender offer SC TO-C

Tender offer

Mar 5

Tender offer SC TO-C

Tender offer

Mar 5

Tender offer SC TO-C

Tender offer

Feb 26

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $4.07B ▲ 6.1% Net income $560.12M ▲ 35.0% Diluted EPS $8.65 ▲ 41.8%

Feb 25

Earnings call

Q4 2024 earnings call

Feb 25

Current report 8-K

Financial results

Jan 13

Current report 8-K

Financial results

Dec 16

Current report 8-K Events of Dec 11

Director or officer change, or executive pay

Nov 26

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation

Nov 21

Current report 8-K Events of Nov 20

Other events

Nov 7

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $1.05B ▲ 8.5% Net income $215.06M ▲ 46.5% Diluted EPS $3.42 ▲ 59.8%

Nov 6

Earnings call

Q3 2024 earnings call

Nov 6

Current report 8-K

Financial results

Oct 16

Current report 8-K Events of Oct 10

Ended a material agreement

Sep 6

Current report 8-K Events of Sep 3

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Other events

Aug 28

Current report 8-K Events of Aug 27

Other events

Aug 1

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $1.02B ▲ 6.9% Net income $168.57M ▲ 61.4% Diluted EPS $2.49 ▲ 63.8%

Jul 31

Earnings call

Q2 2024 earnings call

Jul 31

Current report 8-K

Financial results

Jul 26

Current report 8-K Events of Jul 25

Shareholder vote results

Jul 22

Current report 8-K Events of Jul 19

Entered into a material agreement, New debt or off-balance-sheet obligation

Jul 22

Proxy statement DEFA14A

Proxy statement

Jun 14

Proxy statement DEF 14A Meeting Jul 25, 2024

Proxy statement

Jun 14

Annual report to holders ARS

Annual report to holders

Jun 14

Proxy statement DEFA14A

Proxy statement

Jun 3

Proxy statement PRE 14A Meeting Jul 25, 2024

Proxy statement

May 31

Current report 8-K

Director or officer change, or executive pay

May 2

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $901.98M ▲ 1.0% Net loss $14.62M Diluted EPS -$0.23

May 1

Earnings call

Q1 2024 earnings call

May 1

Current report 8-K

Financial results

Apr 26

Annual report 10-K/A Ended Dec 31

Annual report for the period ended Dec 31, 2023